Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – PsiOxus

Executive Interview – PsiOxus

PsiOxus Therapeutics is an Oxford-based immunotherapy company that has developed a tumour-targeted delivery platform based on its lead oncolytic vaccine, Enadenotucirev (formerly ColoAd1). Enadenotucirev is an oncolytic virus that selectively kills cancer cells by lysis and is currently being studied in four clinical trials in various cancer indications. Under the PsiOxus collaboration with Bristol Myers Squibb, a Phase I combination study of Enadenotucirev with checkpoint inhibitor nivolumab (Opdivo) in a range of tumours, is due to start in Q316. PsiOxus also has a next-generation platform (T-SIGn Therapy) in development. This platform enables the anti-tumour effect of Enadenotucirev to be expanded through the addition of new genes (‘Armed EnAd’) creating a broad range of unique oncolytic immune therapeutics. NG-348, the first product candidate to emerge from this platform, will start Phase I in 2017.

< Previous
Next >

You may also be interested in these:

Consumer

Unlocking London’s hidden tunnels: Investing in a major underground tourist attraction
sharesoc pic

Investment Companies

ShareSoc webinar – The Biotech Growth Trust

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free